JCR Japan College of Rheumatology-
有限責任中間法人 日本リウマチ学会
  会員専用ページ

トップページ
学会案内
沿革
定款
役員・委員会
名誉会員・評議員
学術集会
総会学術集会
歴代総会・学術集会
支部・学術集会
学会教育研修会
国際関連学会
認定制度
リウマチ専門医
リウマチ指導医
教育施設
学会出版物
学会誌MR
NLリウマチ
リウマチ学用語集
会員手続き
本サイトについて
よくある質問
関連リンク集
サイトマップ
プライバシー

MODERN RHEUMATOLOGY Vol.13 No.4

>MR13-4

Antineutrophil cytoplasmic antibodies in patients with Graves disease: association of antimyeloperoxidase autoantibodies with propylthiouracil therapy
Hirokazu Honda1, Takanori Shibata1 , Hideo Hara2, Yoshio Ban2 and Tetsuzo Sugisaki1
(1) Department of Nephrology, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8666, Japan
(2) Third Department of Internal Medicine, Showa University School of Medicine, Tokyo, Japan
 
Received: 04 December 2001 Accepted: 08 April 2003
 
Full Text
  > Click Here (member's only)
 
Abstract
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitic disorders have been reported in patients with Graves disease during propylthiouracil (PTU) therapy. To investigate whether ANCA are found in serum samples from patients with Graves disease, and whether PTU therapy is associated with ANCA positivity, levels of serum ANCA were examined in Graves-disease patients receiving either PTU (n = 49) or 1-methyl-2-mercaptoimidazole (methimazole, MMI) (n = 50), and in untreated Graves-disease patients (n = 32) by enzyme-linked immunosorbent assay (ELISA). Serum samples from patients with Hashimotos thyroiditis (n = 46) were also analyzed. Antimyeloperoxidase (MPO) autoantibodies (MPO-ANCA) were present in 10 (20.4%) of 49 Graves-disease patients receiving PTU therapy, whereas MPO-ANCA were not detected in Graves-disease patients receiving MMI, in untreated Graves-disease patients, or in Hashimotos thyroiditis patients. The MPO-ANCA-positive sera showed a perinuclear staining pattern which was detected by indirect immunofluorescence microscopy using a human polymorphonuclear leukocyte?cytospin preparation. Furthermore, Western blot analysis revealed that MPO-ANCA in the Graves-disease patients, as well as MPO-ANCA in patients with idiopathic pauci-immune necrotizing and crescentic glomerulonephritis, recognize the 105-kD protein of native MPO. These results indicate that MPO-ANCA in Graves-disease patients are strongly associated with PTU therapy, and not simply related to the autoimmune thyroid disease. This study also suggests that the presence of MPO-ANCA alone may not be sufficient for the development of vasculitic disorders.
 
Key words
Antimyeloperoxidase autoantibodies (MPO-ANCA) - Graves disease - Propylthiouracil (PTU)
 
一覧に戻る

Copyright Japan College of Rheumatology All rights reserved.